Fulcrum Therapeutics, Inc. (FULC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 30M 60M 90M Q1 '21: 12.9M Q2 '21: 15.2M Q3 '21: 18.3M Q4 '21: 19.2M Q1 '22: 17M Q2 '22: 14.5M Q3 '22: 10.7M Q4 '22: 6.3M Q1 '23: 4M Q2 '23: 3M Q3 '23: 2.6M Q4 '23: 2.8M Q1 '24: 2.5M Q2 '24: 81.6M Q3 '24: 80.9M Q4 '24: 80M Q1 '25: 80M Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-120M -80M -40M 0 40M 80M 120M Q3 '21: -75.3M Q4 '21: -81.1M Q1 '22: -90M Q2 '22: -104.6M Q3 '22: -108.1M Q4 '22: -112.6M Q1 '23: -114.5M Q2 '23: -107.6M Q3 '23: -110.6M Q4 '23: -110.7M Q1 '24: -112.6M Q2 '24: -32.8M Q3 '24: -30.5M Q4 '24: -21.9M Q1 '25: -12.5M Q2 '25: -84.8M Q3 '25: -81.5M Q4 '25: -84.8M Q1 '26: -86.6M Q2 '26: -96M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-120M -80M -40M 0 40M 80M 120M Q3 '21: -75.1M Q4 '21: -80.8M Q1 '22: -89.8M Q2 '22: -104.2M Q3 '22: -107.2M Q4 '22: -109.9M Q1 '23: -108.7M Q2 '23: -98.4M Q3 '23: -98.7M Q4 '23: -97.3M Q1 '24: -99.4M Q2 '24: -20.2M Q3 '24: -17.9M Q4 '24: -9.7M Q1 '25: -510K Q2 '25: -73.2M Q3 '25: -71.1M Q4 '25: -74.9M Q1 '26: -76.1M Q2 '26: -85M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-105M -70M -35M 0 35M 70M 105M Q3 '21: -76.4M Q4 '21: -78.5M Q1 '22: -84.4M Q2 '22: -93.9M Q3 '22: -99.2M Q4 '22: -97M Q1 '23: -99.1M Q2 '23: -92.5M Q3 '23: -87.5M Q4 '23: -91M Q1 '24: -92.1M Q2 '24: -12.4M Q3 '24: -8.6M Q4 '24: -2.2M Q1 '25: 7.8M Q2 '25: -64.9M Q3 '25: -60M Q4 '25: -60.1M Q1 '26: -63.6M Q2 '26: -65.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-105M -70M -35M 0 35M 70M 105M Q3 '21: -78.1M Q4 '21: -80.2M Q1 '22: -86.1M Q2 '22: -96.4M Q3 '22: -101.6M Q4 '22: -99M Q1 '23: -100.9M Q2 '23: -93.2M Q3 '23: -88M Q4 '23: -91.5M Q1 '24: -92.5M Q2 '24: -12.6M Q3 '24: -8.7M Q4 '24: -2.5M Q1 '25: 7.6M Q2 '25: -65.2M Q3 '25: -60.4M Q4 '25: -60.4M Q1 '26: -63.9M Q2 '26: -66.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q2 '21: 32.6K Q3 '21: 36.6K Q1 '22: 40.6K Q2 '22: 40.9K Q3 '22: 46.2K Q1 '23: 59.7K Q2 '23: 61.8M Q3 '23: 61.8M Q1 '24: 62M Q2 '24: 63.6M Q3 '24: 62.4M Q1 '25: 62.5M Q2 '25: 62.5M Q3 '25: 62.6M Q1 '26: 76.2M Q2 '26: 76.3M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-60.00 -40.00 -20.00 0.00 20.00 40.00 60.00 Q4 '18: -31.14 Q1 '19: -47.73 Q2 '19: -49.44 Q3 '19: -42.33 Q4 '19: -8.13 Q1 '20: 15.35 Q2 '20: 23.90 Q3 '20: 24.17 Q4 '20: -2.80 Q1 '21: -2.53 Q1 '24: -1.60 Q2 '24: -0.35 Q3 '24: -0.31 Q4 '24: -0.16 Q1 '25: -0.01 Q2 '25: -1.16 Q3 '25: -1.12 Q4 '25: -1.18 Q1 '26: -1.15 Q2 '26: -1.21 Q1 '19 Q4 '19 Q3 '20 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.